-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 7, Roche’s subsidiary Genentech and Adaptimmune reached a cooperation to jointly develop allogeneic T cell therapies to treat multiple tumor indications, with a total transaction amount of up to 3 billion US dollars
Adaptimmune stock price trend
From: Yahoo Finance
This partnership covers for up to five undisclosed cancer target share "stock type" (Off-the-shelf) cell therapy research and development and the new allogeneic personalized cell therapy platform development
"Off-the-shelf" Cell Therapy Allogeneic Personalized Cell Therapy Platform
After the transaction is concluded, Adaptimmune will receive an upfront payment of US$150 million and an additional US$150 million in payments over the next five years, as well as development, regulatory and commercial milestone payments and mid-single to low double-digit net sales The total price of tiered royalties may exceed 3 billion US dollars ; in addition, Adaptimmune has the option of 50/50 US profits/components of "off-the-shelf" products.
The total price may exceed 3 billion U.
Dr.
Not only Roche, this company has also reached cooperation with many large pharmaceutical companies
Not only Roche, this company has also reached cooperation with many large pharmaceutical companies
Adaptimmune's clinical stage pipeline
Adaptimmune's early clinical pipeline
The above pictures are from: Adaptimmune official website
Compared with CAR-T therapy, TCR-T has taken the lead in achieving breakthroughs in solid tumors
Compared with CAR-T therapy, TCR-T has taken the lead in achieving breakthroughs in solid tumors
Edit edit : add one
PR draft docking : WeChat insightxb
PR draft docking PR draft docking : WeChat insightxbContribution : WeChat insightxb; Email insight@dxy.
Submission Submission : micro-channel insightxb; mailbox insight@dxy.
cn